Jie Zhang1, Xin-Juan Sun2, Jin'an Chen3, Zhi Wei Hu4, Lei Wang5, Dong Mei Gu6, Ai-Ping Wang7. 1. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. Electronic address: xiaopengyou1226@sina.com. 2. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. Electronic address: 27966509@qq.com. 3. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. Electronic address: cysc111@163.com. 4. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. Electronic address: huzhiwei_yu1208@163.com. 5. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. Electronic address: 872819805@qq.com. 6. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. 7. The 454th Hospital of Chinese PLA, Nanjing Road Street Baixia District No.1, Nanjing 210002, China. Electronic address: wap454hospital@hotmail.com.
Abstract
BACKGROUND: miR-126 may increase angiogenesis in patients with diabetic foot ulcers (DFUs) treated with maggot debridement therapy (MDT). METHODS: Real-time quantitative PCR was used to detect expression of miR-126 mRNA in the peripheral blood among the non-diabetic population, type 2 diabetes mellitus patients without DFU, and patients with DFUs of type 2 diabetes mellitus. The expression of miR-126 mRNA in the peripheral blood of patients with DFUs was observed before and after MDT. Finally, human umbilical vein endothelial cells (HUVEC) were utilized to explore miR-126 mRNA expression with maggot excretions/secretions (ES). RESULTS: In the patients with DFUs, the miR-126 mRNA expression level in the peripheral blood was less than that type 2 diabetes mellitus patients without DFU, and much lower than that in the non-diabetic population (P<0.001). The miR-126 expression level was significantly increased in those DFU patients treated with MDT (P<0.05). Finally, using HUVEC co-cultured with ES, we showed the ES increased miR-126 expression in vitro (P<0.001). CONCLUSION: MDT upregulates the miR-126 expression in the peripheral blood of patients with DFUs.
BACKGROUND:miR-126 may increase angiogenesis in patients with diabetic foot ulcers (DFUs) treated with maggot debridement therapy (MDT). METHODS: Real-time quantitative PCR was used to detect expression of miR-126 mRNA in the peripheral blood among the non-diabetic population, type 2 diabetes mellituspatients without DFU, and patients with DFUs of type 2 diabetes mellitus. The expression of miR-126 mRNA in the peripheral blood of patients with DFUs was observed before and after MDT. Finally, human umbilical vein endothelial cells (HUVEC) were utilized to explore miR-126 mRNA expression with maggot excretions/secretions (ES). RESULTS: In the patients with DFUs, the miR-126 mRNA expression level in the peripheral blood was less than that type 2 diabetes mellituspatients without DFU, and much lower than that in the non-diabetic population (P<0.001). The miR-126 expression level was significantly increased in those DFU patients treated with MDT (P<0.05). Finally, using HUVEC co-cultured with ES, we showed the ES increased miR-126 expression in vitro (P<0.001). CONCLUSION: MDT upregulates the miR-126 expression in the peripheral blood of patients with DFUs.
Authors: Irena Pastar; Jelena Marjanovic; Rivka C Stone; Vivien Chen; Jamie L Burgess; Joshua S Mervis; Marjana Tomic-Canic Journal: Exp Dermatol Date: 2021-04-01 Impact factor: 4.511